Cipla cuts prices of 3 cancer drugs by up to 64%

Drugmaker Cipla cut prices of three cancer drugs between 50 percent and 64 percent with immediate effect, after it announced similar price cuts for three drugs early this year.

Lung cancer drug Erlocip would cost Rs 9,900 for 30 tablets instead of Rs 27,000 earlier, while breast cancer treatment Docetax would be priced 1,650 rupees instead of Rs 3,300, Cipla said in a statement on Thursday.

Cipla last month won a case against Roche Holding , which accused the Indian company of infringing patent on cancer drug Tarceva, which Cipla sells under the brand name Erlocip.

Capegard, another drug to treat metastatic colorectal and colon caner, would be priced 600 rupees for 10 tablets instead of Rs 1,200, it said.

Anda sedang membaca artikel tentang

Cipla cuts prices of 3 cancer drugs by up to 64%

Dengan url

https://kesehatanda.blogspot.com/2012/11/cipla-cuts-prices-of-3-cancer-drugs-by.html

Anda boleh menyebar luaskannya atau mengcopy paste-nya

Cipla cuts prices of 3 cancer drugs by up to 64%

namun jangan lupa untuk meletakkan link

Cipla cuts prices of 3 cancer drugs by up to 64%

sebagai sumbernya